Instead, in MM where plasma cells are terminally differentiated it acts via the interaction with different targets such as Myeloid cell leukemia-1 (MCL-1), an inhibitor of apoptosis, to cause drug resistance in different tumor diseases [48,49]. This evidence concerns the gene MCL1 and neoplasm.